RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
Clinical trials for RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lymphoma: experimental drug ICP-248 targets relapsed MCL
Disease control Recruiting nowThis study tests an experimental drug called ICP-248 in 75 adults whose mantle cell lymphoma has returned or stopped responding to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. This is a phase 2 trial, meaning it checks both safet…
Matched conditions: RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 06:02 UTC
-
New combo therapy offers hope for aggressive lymphoma patients
Disease control Recruiting nowThis study tests a combination of two drugs, glofitamab and lenalidomide, in 43 adults with a type of blood cancer called mantle cell lymphoma that has returned or not responded to treatment, especially after a BTK inhibitor stopped working. Participants receive glofitamab throug…
Matched conditions: RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Peking University Third Hospital • Aim: Disease control
Last updated May 26, 2026 05:49 UTC